Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast

J Clin Rheumatol. 2021 Dec 1;27(8S):S561-S562. doi: 10.1097/RHU.0000000000000999.

Abstract

Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathy with characteristic cutaneous manifestations and muscle weakness. Conventional treatments for DM include glucocorticoids and other immunosuppressive or immunomodulatory agents including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, and intravenous immunoglobulin. Refractory patients require more aggressive or novel therapies. Apremilast has not been studied for the management of refractory cutaneous DM. We report a case of a patient with refractory DM with severe scalp pruritus treated with apremilast who demonstrated significant improvement in her skin disease and complete resolution of scalp pruritus.

Publication types

  • Case Reports

MeSH terms

  • Dermatomyositis* / complications
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / drug therapy
  • Female
  • Humans
  • Immunomodulating Agents
  • Immunosuppressive Agents
  • Pruritus / diagnosis
  • Pruritus / drug therapy
  • Pruritus / etiology
  • Scalp
  • Thalidomide / analogs & derivatives

Substances

  • Immunomodulating Agents
  • Immunosuppressive Agents
  • Thalidomide
  • apremilast